Cardiac Fibrosis
10
1
3
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
10.0%
1 terminated out of 10 trials
83.3%
-3.2% vs benchmark
10%
1 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (10)
The Effects of Inositol on Glucose Metabolism in Patients With Metabolic Syndrome at Risk of Cardiac Fibrosis
Effect of Genetic Polymorphism on the Clinical Outcome to SGLT2 Inhibitors in Heart Failure Patients
Pilot Study of Cardiac MR in Patients With Muscular Dystrophy
Metformin Use in Cardiac Fibrosis in PAI-1 Deficiency
Immune Correlates of Cardiac Structure and Function
Characterization of Heart Failure With Preserved Ejection Fraction
Early MRI Detection of Myocardial Deterioration as a Preventive, Disease Staging, and Prognostic Biomarker in Insulin Resistance
Cardiovascular Fibrosis in Idiopathic Pulmonary Fibrosis
Circulating P3NP and Cardiovascular Events in Hemodialysis Patients
Effects of Pycnogenol on Cardiac Fibrosis and Diastolic Dysfunction in Aged Hypertensive Subjects